Department of Obstetrics and Gynecology and the Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina
Auto-generated profile, based on publicly available information
Jenny Wu
Department of Obstetrics and Gynecology and the Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina
TikTok, a video-sharing application, offers a growing platform for contraception-related content. The top 100 videos tagged “#IUD” were compiled using a web-scraping application. User demographics and video content were analyzed by two independent reviewers, with a third to arbitrate differences. More videos had a negative tone (37.8%) about intrauterine devices (IUDs) than positive (19.4%), and 27.6% mentioned distrust of health care professionals. Of videos conveying patient experiences, all had a negative or ambiguous tone and 96.8% highlighted pain and other side effects related to IUDs. Videos scored low on information health quality (1.2/5 on DISCERN) and averaged 73.8% in understandability and 17.7% in actionability on PEMAT (Patient Education Materials Assessment Tool). #IUD videos on TikTok often portray negative experiences related to pain and informed consent.
1 August 2020 in JNCI: Journal of the National Cancer Institute
Background: Health reform and the merits of Medicaid expansion remain at the top of the legislative agenda, with growing evidence suggesting an impact on cancer care and outcomes. A systematic review was undertaken to assess the association between Medicaid expansion and the goals of the Patient Protection and Affordable Care Act in the context of cancer care. The purpose of this article is to summarize the currently published literature and to determine the effects of Medicaid expansion on outcomes during points along the cancer care continuum. Methods: A systematic search for relevant studies was performed in the PubMed/MEDLINE, EMBASE, Scopus, and Cochrane databases. Three independent observers used an abstraction form to code outcomes and perform a quality and risk of bias assessment using predefined criteria. Results: A total of 48 studies were identified. The most common outcomes assessed were the impact of Medicaid expansion on insurance coverage (23.4% of studies), followed by evaluation of racial and/or socioeconomic disparities (17.4%) and access to screening (14.5%). Medicaid expansion was associated with increases in coverage for cancer patients and survivors as well as reduced racial- and income-related disparities. Conclusions: Medicaid expansion has led to improved access to insurance coverage among cancer patients and survivors, particularly among low-income and minority populations. This review highlights important gaps in the existing oncology literature, including a lack of studies evaluating changes in treatment and access to end-of-life care following implementation of expansion.
While primary cytoreductive surgery (PCS) is considered the standard of care for women who present with stage IV endometrial cancer, neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS) has emerged as an alternative treatment strategy. We summarized the literature and compared outcomes of PCS compared to NACT and ICS. We conducted a systematic search on PubMed, Embase, Web of Science, and Scopus for articles published from January 1, 1990 to December 31, 2020. Key search terms included multiple descriptors of advanced disease status in combination with “endometrial cancer” and “neoadjuvant chemotherapy”. Our review included studies that examined survival and surgical outcomes of patients with stage III or IV endometrial cancer treated with neoadjuvant chemotherapy followed by interval cytoreductive surgery versus those who received primary cytoreductive surgery. We excluded studies examining only patients with leiomyosarcomas, carcinosarcomas, and stromal sarcomas due to the biologic heterogeneity of these malignancies. The nine included studies encompassed 5,844 patients, of which 1,317 (22.5%) received NACT and 4,527 received PCS (77.5%). With the exception of a single study, all were retrospective observational studies or case series. Use of NACT in patients with stage IV EC increased from 16.0% in 2010 to 23.9% in 2015. Five studies analyzed median overall survival and all but one reported no significant difference between NACT + ICS vs. PCS. Optimal cytoreduction (<1 cm of residual disease) rates were similar across both treatment groups in three separate analyses, however pooled data suggest improved rates of optimal cytoreduction for NACT + ICS vs. PCS patients (81.9% vs. 51.5% respectively). Patients receiving NACT experienced significantly shorter hospital admissions and lower operative times compared to PCS counterparts. NACT followed by ICS reduces perioperative morbidity while offering similar overall survival.
31 January 2023 in American Journal of Obstetrics and Gynecology